Pathogenesis and treatment of ANCA-associated systemic vasculitis

Pusey CD. Vasculitis and rapidly progressive glomerulonephritis. In: Savill J ed. Horizons in Medicine. Vol. 9. London: Royal College of Physicians of London, 1998: 85–94.

Savage COS , Harper L , Adu D. Primary systemic vasculitis. Lancet 1997; 349: 553–8.

Jennette JC , Falk RJ , Andrassy K Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994; 37: 187–92.

Jennette JC , Falk RJ. Small-vessel vasculitis. N Engl J Med 1997; 337: 1512–23.

Ewert BH , Jennette JC , Falk RJ. The pathogenic role of antineutrophil cytoplasmic autoantibodies. Am J Kidney Dis 1991; 18: 188–95.

Charles LA , Caldas ML , Falk RJ , Terrell RS , Jennette JC. Antibodies against granule proteins activate neutrophils in vitro. J Leukoc Biol 1991; 50: 539–46.

Reumax D , Vossebeld PJ , Roos D , Verhoeven AJ. Effect of tumor necrosis factor-induced integrin activation on Fc gamma receptor II-mediated signal transduction: relevance for activation of neutrophils by anti-proteinase 3 or anti-myeloperoxidase antibodies. Blood 1995; 86: 3189–95.

Gilligan HM , Bredy B , Brady HR Antineutrophil cytoplasmic autoantibodies interact with primary granule constituents on the surface of apoptotic neutrophils in the absence of neutrophil priming. J Exp Med 1996; 184: 2231–41.

Savage CO , Gaskin G , Pusey CD , Pearson JD. Anti-neutrophil cytoplasm antibodies can recognize vascular endothelial cell-bound anti-neutrophil cytoplasm antibody-associated autoantigens. Exp Nephrol 1993; 1: 190–5.

Sibelius U , Hattar K , Schenkel A Wegener's granulomatosis: anti-proteinase 3 antibodies are potent inductors of human endothelial cell signaling and leakage response. J Exp Med 1998; 187: 497–503.

Dolman KM , van de Wiel BA , Kam CM Proteinase 3: substrate specificity and possible pathogenetic effect of Wegener's granulomatosis autoantibodies (c-ANCA) by dysregulation of the enzyme. Adv Exp Med Bio 1993; 336: 55–60.

Esnault VL , Testa A , Audrain M Alpha 1-antitrypsin genetic polymorphism in ANCA-positive systemic vasculitis. Kidney Int 1993; 43: 1329–32.

Griffith ME , Lovegrove JU , Gaskin G , Whitehouse DB , Pusey CD. C-antineutrophil cytoplasmic antibody positivity in vasculitis patients is associated with the Z allele of alpha-1-antitrypsin, and P-antineutrophil cytoplasmic antibody positivity with the S allele. Nephrol Dial Transplant 1996; 11: 438–43.

Gaskin G , Pusey CD. Clinical aspects of systemic vasculitis. In: Pusey CD , Rees AJ eds. Rapidly Progressive Glomerulonephritis. Oxford: Oxford University Press, 1998: 125–48.

Gaskin G , Savage CO , Ryan JJ Anti-neutrophil cytoplasmic antibodies and disease activity during long-term follow-up of 70 patients with systemic vasculitis. Nephrol Dial Transplant 1991; 6: 689–94.

Jayne DR , Gaskin G , Pusey CD , Lockwood CM. ANCA and predicting relapse in systemic vasculitis. Quart J Med 1995; 88: 127–33.

De'Oliviera J , Gaskin G , Dash A , Rees AJ , Pusey CD. Relationship between disease activity and anti-neutrophil cytoplasmic antibody concentration in long-term management of systemic vasculitis. Am J Kidney Dis 1995; 25: 380–9.

Tervaert JWC , Huitema MG , Hene RW Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre. Lancet 1990; 336: 709–11.

Dolman KM , Gans RO , Vervaat TJ Vasculitis and antineutrophil cytoplasmic autoantibodies associated with propylthiouracil therapy. Lancet 1993; 342: 651–2.

Vogt BA , Kim Y , Jennette JC , Falk RJ , Burke BA , Sinalko A. Antineutrophil cytoplasmic autoantibody-positive crescentic glomerulonephritis as a complication of treatment with propylthiouracil in children. J Pediatr 1994; 124: 986–8.

D'Cruz D , Chesser AM , Lightowler C Antineutrophil cytoplamic antibody-positive crescentic glomerulonephritis associated with anti-thyroid drug treatment. Br J Rheumatol 1995; 34: 1090–1.

Heeringa P , Brouwer E , Cohen Tervaert JW , Weening JJ , Kallenberg CG. Animal models of anti-neutrophil cytoplasmic antibody associated vasculitis. Kidney Int 1998; 53: 253–63.

Griffith ME , Pusey CD. HLA genes in ANCA-associated vasculitides. Exp Clin Immunogenet 1997; 14: 196–205.

Griffith ME , Coulthart A , Pusey CD. T cell responses to myeloperoxidase (MPO) and proteinase 3 (PR3) in patients with systemic vasculitis. Clin Exp Immunol 1996; 103: 253–8.

Giscombe R , Grunewald J , Nityanand S , Lefvert AK. T cell receptor (TCR) V gene usage in patients with systemic necrotizing vasculitis. Clin Exp Immunol 1995; 101: 213–19.

Simpson IJ , Skinner MA , Geursen A Peripheral blood T lymphocytes in systemic vasculitis: increased T cell receptor V beta 2 gene usage in microscopic polyarteritis. Clin Exp Immunol 1995; 101: 220–6.

Stegeman CA , Cohen Tervaert JW , Huiterna MG , Kallenberg CG. Serum markers of T cell activation in relapses of Wegener's granulomatosis. Clin Exp Immunol 1993; 91: 415–20.

Ludviksson BR , Sneller MC , Chua KS Active Wegener's granulomatosis is associated with HLA — DR+CD₄+T cells exhibiting an unbalanced Th1-type T cell cytokine pattern: reversal with IL-10. J Immunol 1998; 160: 3602–9.

Schmitt WH , Heesen C , Csernok E , Rautmann A , Gross WL. Elevated serum levels of soluble interleukin-2 receptor in patients with Wegener's granulomatosis. Association with disease activity. Arthritis Rheum 1992; 35: 1088–96.

Pinching AJ , Rees AJ , Pussell BA , Lockwood CM , Mitchison RS , Peters DK. Relapses in Wegener's granulomatosis: the role of infection. BMJ 1980; 281: 836–8.

Sitara D , Hoffbrand D. Chronic bronchial suppuration and antineutrophil cytoplasmic antibody (ANCA) positive systemic vasculitis. Postgrad Med J 1990; 66: 669–71.

Stegeman CA , Cohen Tervaert JW , Kallenberg CG. Anti-neutrophil cytoplasmic antibodies: tools for diagnosis and follow-up in systemic vasculitis. Ann Méd Interne Paris 1994; 145: 523–32.

Stegeman CA , Cohen Tervaert JW , de Jong PE , Kallenberg CG. Trimethoprim—sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med 1996; 335: 16–20.

Fauci AS , Haynes BF , Katz P , Wolff SM. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983; 98: 76–85.

Jayne DR , Tasmussen N. Treatment of antineutrophil cytoplasm autoantibody—associated systemic vasculitis: initiatives of the European Community Systemic Vasculitis Clinical Trials Study Group. Mayo Clin Proc 1997; 72: 737–47.

Pusey CD , Rees AJ , Evans DJ , Peters DK , Lockwood CM. Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies. Kidney Int 1991; 40: 757–63.

Jayne DRW , Davies MJ , Fox CJ , Black CM. Treatment of systemic vasculitis with pooled intravenous immunoglobulin. Lancet 1991; 337: 1137–9.

Lockwood CM , Thiru S , Stewart S Treatment of refractory Wegener's granulomatosis with humanized monoclonal antibodies. Quart J Med 1996; 89: 903–12.

Exley AR , Carruthers DM , Luqmani RA Damage occurs early in systemic vasculitis and is an index of outcome. Quart J Med 1997; 90: 391–9.

Allen A , Pusey CD , Gaskin G. Outcome of renal replacement therapy in antineutrophil cytoplasmic antibody—associated systemic vasculitis. J Am Soc Nephrol 1998; 9: 1258–63.